FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010140068> ?p ?o ?g. }

• W2010140068 endingPage "1002" @default.
• W2010140068 startingPage "990" @default.
• W2010140068 abstract "β2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis.BackgroundA local inflammatory reaction to β2-microglobulin (β2m) amyloid deposits by monocytes/macrophages is a characteristic histologic feature of dialysis-related amyloidosis (DRA). Since β2m modified with advanced glycation end products (AGE-β2m) is a major constituent of amyloid in DRA, we tested the hypothesis that AGE-β2m affects apoptosis and phenotype of human monocytes.MethodsHuman peripheral blood monocytes were incubated with or without in vitro-derived AGE-β2m, and their viability, extent of apoptosis, morphology, and function examined over the subsequent four days.ResultsAGE-modified but not unmodified β2m significantly delayed spontaneous apoptosis of human peripheral blood monocytes in adherent and nonadherent cultures. The effect of AGE-β2m on monocytes apoptosis was time- and dose-dependent and was attenuated by a blocking antibody directed against the human AGE receptor (RAGE). There was no difference in effect between AGE-β2m and that of AGE-modified human serum albumin. Culture of monocytes with AGE-β2m did not alter membrane expression of Fas or Fas ligand. Monocytes cultured with AGE-β2m underwent substantial changes in morphology similar to those observed when monocytes differentiate into macrophages. The cultured cells increased in size and vacuolization, and their content of β-glucuronidase and acid phosphatase increased by 5- to 10-fold at day 4. Expression of the monocyte–macrophage membrane antigens HLA-DR, CD11b, and CD11c also increased at day 4. Although exhibiting phenotypic characteristics of macrophages, monocytes cultured with AGE-β2m functioned differently than macrophages cultured with serum. Superoxide production in response to phorbol myristic acetate was maintained in monocytes cultured with AGE-β2m, but declined with time in cells cultured with serum. Constitutive synthesis of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and prostaglandin E2 (PGE2) increased in monocytes cultured for four to six days with AGE-β2m.ConclusionsThese findings support a novel role for AGE-modified proteins such as AGE-β2m that may contribute to the development of a local inflammatory response, with predominant accumulation of monocytes/macrophages, in DRA. β2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. A local inflammatory reaction to β2-microglobulin (β2m) amyloid deposits by monocytes/macrophages is a characteristic histologic feature of dialysis-related amyloidosis (DRA). Since β2m modified with advanced glycation end products (AGE-β2m) is a major constituent of amyloid in DRA, we tested the hypothesis that AGE-β2m affects apoptosis and phenotype of human monocytes. Human peripheral blood monocytes were incubated with or without in vitro-derived AGE-β2m, and their viability, extent of apoptosis, morphology, and function examined over the subsequent four days. AGE-modified but not unmodified β2m significantly delayed spontaneous apoptosis of human peripheral blood monocytes in adherent and nonadherent cultures. The effect of AGE-β2m on monocytes apoptosis was time- and dose-dependent and was attenuated by a blocking antibody directed against the human AGE receptor (RAGE). There was no difference in effect between AGE-β2m and that of AGE-modified human serum albumin. Culture of monocytes with AGE-β2m did not alter membrane expression of Fas or Fas ligand. Monocytes cultured with AGE-β2m underwent substantial changes in morphology similar to those observed when monocytes differentiate into macrophages. The cultured cells increased in size and vacuolization, and their content of β-glucuronidase and acid phosphatase increased by 5- to 10-fold at day 4. Expression of the monocyte–macrophage membrane antigens HLA-DR, CD11b, and CD11c also increased at day 4. Although exhibiting phenotypic characteristics of macrophages, monocytes cultured with AGE-β2m functioned differently than macrophages cultured with serum. Superoxide production in response to phorbol myristic acetate was maintained in monocytes cultured with AGE-β2m, but declined with time in cells cultured with serum. Constitutive synthesis of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and prostaglandin E2 (PGE2) increased in monocytes cultured for four to six days with AGE-β2m. These findings support a novel role for AGE-modified proteins such as AGE-β2m that may contribute to the development of a local inflammatory response, with predominant accumulation of monocytes/macrophages, in DRA." @default.
• W2010140068 created "2016-06-24" @default.
• W2010140068 creator A5007603996 @default.
• W2010140068 creator A5014300179 @default.
• W2010140068 creator A5027299023 @default.
• W2010140068 creator A5028063859 @default.
• W2010140068 creator A5035243369 @default.
• W2010140068 creator A5055632609 @default.
• W2010140068 creator A5071917576 @default.
• W2010140068 creator A5090933484 @default.
• W2010140068 date "2001-03-01" @default.
• W2010140068 modified "2023-10-16" @default.
• W2010140068 title "β2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis" @default.
• W2010140068 cites W1481381887 @default.
• W2010140068 cites W1575774937 @default.
• W2010140068 cites W1594856996 @default.
• W2010140068 cites W1963673812 @default.
• W2010140068 cites W1969493549 @default.
• W2010140068 cites W1980713903 @default.
• W2010140068 cites W1992710979 @default.
• W2010140068 cites W2003739985 @default.
• W2010140068 cites W2017986559 @default.
• W2010140068 cites W2023991682 @default.
• W2010140068 cites W2026782054 @default.
• W2010140068 cites W2035280748 @default.
• W2010140068 cites W2036937264 @default.
• W2010140068 cites W2038238875 @default.
• W2010140068 cites W2042854938 @default.
• W2010140068 cites W2057616008 @default.
• W2010140068 cites W2065012620 @default.
• W2010140068 cites W2072692635 @default.
• W2010140068 cites W2074387820 @default.
• W2010140068 cites W2081313045 @default.
• W2010140068 cites W2086959096 @default.
• W2010140068 cites W2096747831 @default.
• W2010140068 cites W2104398626 @default.
• W2010140068 cites W2107438874 @default.
• W2010140068 cites W2113990199 @default.
• W2010140068 cites W2129795201 @default.
• W2010140068 cites W2138302361 @default.
• W2010140068 cites W2146989945 @default.
• W2010140068 cites W2157710456 @default.
• W2010140068 cites W2159767378 @default.
• W2010140068 cites W2163326592 @default.
• W2010140068 cites W2209920720 @default.
• W2010140068 cites W4229662680 @default.
• W2010140068 cites W57366046 @default.
• W2010140068 doi "https://doi.org/10.1046/j.1523-1755.2001.059003990.x" @default.
• W2010140068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11231354" @default.
• W2010140068 hasPublicationYear "2001" @default.
• W2010140068 type Work @default.
• W2010140068 sameAs 2010140068 @default.
• W2010140068 citedByCount "64" @default.
• W2010140068 countsByYear W20101400682012 @default.
• W2010140068 countsByYear W20101400682013 @default.
• W2010140068 countsByYear W20101400682014 @default.
• W2010140068 countsByYear W20101400682015 @default.
• W2010140068 countsByYear W20101400682016 @default.
• W2010140068 countsByYear W20101400682017 @default.
• W2010140068 countsByYear W20101400682018 @default.
• W2010140068 countsByYear W20101400682019 @default.
• W2010140068 countsByYear W20101400682020 @default.
• W2010140068 countsByYear W20101400682022 @default.
• W2010140068 crossrefType "journal-article" @default.
• W2010140068 hasAuthorship W2010140068A5007603996 @default.
• W2010140068 hasAuthorship W2010140068A5014300179 @default.
• W2010140068 hasAuthorship W2010140068A5027299023 @default.
• W2010140068 hasAuthorship W2010140068A5028063859 @default.
• W2010140068 hasAuthorship W2010140068A5035243369 @default.
• W2010140068 hasAuthorship W2010140068A5055632609 @default.
• W2010140068 hasAuthorship W2010140068A5071917576 @default.
• W2010140068 hasAuthorship W2010140068A5090933484 @default.
• W2010140068 hasBestOaLocation W20101400681 @default.
• W2010140068 hasConcept C126322002 @default.
• W2010140068 hasConcept C134018914 @default.
• W2010140068 hasConcept C147990577 @default.
• W2010140068 hasConcept C153911025 @default.
• W2010140068 hasConcept C170493617 @default.
• W2010140068 hasConcept C185592680 @default.
• W2010140068 hasConcept C190283241 @default.
• W2010140068 hasConcept C202751555 @default.
• W2010140068 hasConcept C203014093 @default.
• W2010140068 hasConcept C2779244956 @default.
• W2010140068 hasConcept C2781184567 @default.
• W2010140068 hasConcept C55493867 @default.
• W2010140068 hasConcept C71924100 @default.
• W2010140068 hasConcept C86803240 @default.
• W2010140068 hasConcept C88634738 @default.
• W2010140068 hasConceptScore W2010140068C126322002 @default.
• W2010140068 hasConceptScore W2010140068C134018914 @default.
• W2010140068 hasConceptScore W2010140068C147990577 @default.
• W2010140068 hasConceptScore W2010140068C153911025 @default.
• W2010140068 hasConceptScore W2010140068C170493617 @default.
• W2010140068 hasConceptScore W2010140068C185592680 @default.
• W2010140068 hasConceptScore W2010140068C190283241 @default.
• W2010140068 hasConceptScore W2010140068C202751555 @default.
• W2010140068 hasConceptScore W2010140068C203014093 @default.
• W2010140068 hasConceptScore W2010140068C2779244956 @default.

• next